Chronic Obstructive Pulmonary Disease Market Report by DelveInsight

DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Market report puts forward a detailed perspective on epidemiology, current treatment practices, emerging drugs, COPD market share of the individual therapies, current and forecasted Chronic Obstructive Pulmonary Disease market size for the study period 2018 to 2030 spanning across 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Key highlights from the Chronic Obstructive Pulmonary Disease Market report: 

• Key pharma companies actively pushing the pace of drug development in the Chronic Obstructive Pulmonary Disease market include Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Tetherex Pharmaceuticals, Verona Pharma, Vertex Pharmaceuticals, and several others. 
• The two biologics in the COPD pipeline, GSK's Nucala (mepolizumab) and AstraZeneca's Benralizumab, are the only therapies offering a novel mechanism of action. 
• The approved bronchodilators for the treatment of COPD include Stiolto Respimat (Boehringer Ingelheim), Spiriva Respimat and Spiriva Handihaler (Boehringer Ingelheim), Striverdi Respimat (Boehringer Ingelheim), Incruse Ellipta (GlaxoSmithKline), Tudorza Pressair (Forest Laboratories), Yupelri (Theravance Biopharma).

Download Sample report to understand which drug is going to nab the maximum market share @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease Epidemiology

Chronic Obstructive Pulmonary Disease is currently the third most common cause of global morbidity and mortality. As per COPD epidemiological analysis, COPD is primarily present in smokers, especially in the age group >40 years. The COPD prevalence increases with the age, however, the prevalence is most likely underestimated owing to the underdiagnosis of COPD.

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Visit for deep insights into Chronic Obstructive Pulmonary Disease patient pool @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease Therapy Market 

The primary goal of COPD treatment remains alleviating symptoms and addressing exacerbations, reducing mortality rate, and altering the underlying nature of the disease (otherwise known as 'disease modification').

Currently, there are 9 approved drug categories for COPD maintenance medication. However, the majority of these available treatment options are largely iterations of bronchodilators, which open airways and but no pharmacological treatment has the potential to prevent the progression of lung destruction. The only way to stop the disease from getting worse is to stop smoking. 

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Check out for more @ Chronic Obstructive Pulmonary Disease Market Forecast

COPD Available Therapies and Treatment Options 

• Bronchodilators
• Short-Acting Beta-2 Agonists
• Long-Acting Beta-2 Agonists
• Anticholinergic Agents
• Anti-inflammatory Drugs
• Oral and Inhaled Corticosteroids
• Anti-leukotrienes
• Phosphodiesterase Type-4 Inhibitors
• Other Anti-inflammatory Drugs
• Monoclonal Antibodies
• Combination Drugs

Chronic Obstructive Pulmonary Disease Market

The Chronic Obstructive Pulmonary Disease market is expected to swell up owing to the major traction of the pharma companies investing in the domain, awareness, healthcare funding, and novel therapeutic advances. More than 60 therapies are in different stages of development. Major players such as Afimmune, Inmunotek S.L., Sanofi, Regeneron, Pulmotect, Verona Pharma, and several others are investigating their therapies in the late-stage trials and continually working to strengthen the COPD drug pipeline. 

Inmunotek S.L. is investigating its MV130, a bacterial mucosal vaccine spray, stimulates dendritic cells to modulate the functional activity of the innate and adaptive immune response. The company is currently conducting a Phase III trial to evaluate the efficacy and safety of MV130 in patients with COPD. 

The duo, Sanofi/Regeneron, is targeting two key proteins that are thought to play a central role in type 2 inflammation. The companies are investigating a fully human monoclonal antibody, SAR440340, that inhibits interleukin-33 (IL-33), and a targeted biologic therapy, Dupilumab, that along with inhibiting signaling of interleukin-13 (IL-13) also inhibits interleukin-4 (IL-4) signaling. Both the agents are in the Phase III trial for the treatment of COPD. 

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Key Pharma Companies in the Chronic Obstructive Pulmonary Disease Market

• Afimmune
• Allakos
• Amgen/AstraZeneca
• Arrowhead Pharmaceuticals
• Astellas Pharma
• AstraZeneca
• Boehringer-Ingelheim
• Brickell Biotech
• Chiesi Farmaceutici S.p.A.
• CHIESI USA, Inc.
• Dimerix
• EpiEndo Pharmaceuticals
• Genentech
• GlaxoSmithKline
• GSNOR Therapeutics
• InMed Pharmaceuticals
• Ionis Pharmaceuticals
• KeyMed Biosciences
• Laboratoires SMB
• Mereo BioPharma
• Meridigen Biotech
• Nephron Pharmaceuticals
• Novartis
• Pulmatrix Inc.
• Pulmotect
• Quercegen Pharmaceuticals
• Regend Therapeutics
• Regeneron Pharmaceuticals/Sanofi
• Sulfateq BV
• Synairgen
• Tetherex Pharmaceuticals
• Verona Pharma
• Vertex Pharmaceuticals
• Yungjin Pharm. Co., Ltd.